TScan Therapeutics (TCRX) Earnings Date, Estimates & Call Transcripts $1.45 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TScan Therapeutics Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 12EstimatedActual EPS (Mar. 5) -$0.29 Missed By -$0.02 Consensus EPS (Mar. 5) -$0.27 TScan Therapeutics released Q4 2024 earnings on March 5, 2025, reporting an EPS of -$0.29, which missed analysts' consensus estimates of -$0.27 by $0.02. Quarterly revenue was reported to be $0.67 million, below analysts' expectations of $1.43 million. With a trailing EPS of -$1.15, TScan Therapeutics' earnings are expected to decrease next year, from ($1.12) to ($1.14) per share. TCRX Upcoming EarningsTScan Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based off prior year's reporting schedules. Get TScan Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTCRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TCRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads TScan Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.25-$0.25-$0.25Q2 20252-$0.32-$0.26-$0.29Q3 20251-$0.26-$0.26-$0.26Q4 20251-$0.22-$0.22-$0.22FY 20255($1.05)($0.99)($1.02) Remove Ads TScan Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/12/2025(Estimated)-------3/5/2025Q4 2024-$0.27-$0.29 -$0.02-$0.30$1.43M$0.67M11/12/2024--$0.28-$0.25+$0.03-$0.25$2.86M$1.05M8/12/2024--$0.30-$0.28+$0.02-$0.28$1.55M$0.54M5/13/2024Q1 2024-$0.25-$0.32 -$0.07-$0.32$3.75M$0.57M3/6/2024Q4 2023-$0.29-$0.21+$0.08-$0.21$2.94M$7.21M11/9/2023Q3 2023-$0.43-$0.24+$0.19-$0.24$3.80M$3.89M8/10/2023Q2 2023-$0.76-$0.51+$0.25-$0.51$3.75M$3.15M5/10/2023Q1 2023-$0.73-$0.93 -$0.20-$0.93$3.10M$6.80M TScan Therapeutics Earnings - Frequently Asked Questions When is TScan Therapeutics's earnings date? TScan Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based off last year's report dates. Learn more on TCRX's earnings history. Did TScan Therapeutics beat their earnings estimates last quarter? In the previous quarter, TScan Therapeutics (NASDAQ:TCRX) missed the analysts' consensus estimate of ($0.27) by $0.02 with a reported earnings per share (EPS) of ($0.29). Learn more on analysts' earnings estimate vs. TCRX's actual earnings. How much revenue does TScan Therapeutics generate each year? TScan Therapeutics (NASDAQ:TCRX) has a recorded annual revenue of $2.82 million. How much profit does TScan Therapeutics generate each year? TScan Therapeutics (NASDAQ:TCRX) has a recorded net income of -$89.22 million. TCRX has generated -$1.15 earnings per share over the last four quarters. What is TScan Therapeutics's EPS forecast for next year? TScan Therapeutics's earnings are expected to decrease from ($1.12) per share to ($1.14) per share in the next year. More Earnings Resources from MarketBeat Related Companies Arcturus Therapeutics Earnings Results Astria Therapeutics Earnings Results Monte Rosa Therapeutics Earnings Results Cryoport Earnings Results Aura Biosciences Earnings Results Esperion Therapeutics Earnings Results Alpha Teknova Earnings Results Taysha Gene Therapies Earnings Results Benitec Biopharma Earnings Results Amylyx Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Remove Ads This page (NASDAQ:TCRX) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
